22Jan 2024
Bempedoic Acid Shows Significant Reduction in Cardiovascular Events, Study Finds

Bempedoic Acid Shows Significant Reduction in Cardiovascular Events, Study Finds

A recent analysis of Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial focused on assessing the impact of bempedoic acid on major adverse cardiovascular events (MACE). The study, conducted from December 2016 to November 2022, involved 13,970 high-risk cardiovascular patients unable to take standard statins. Those treated with bempedoic acid experienced a 21% reduction in LDL-C and a 22% decrease in hsCRP levels, resulting in a noteworthy reduction in MACE-4 risk (hazard ratio [HR], 0.80; 95% CI, 0.72-0.89; P <.001). These findings emphasize the cardioprotective potential of bempedoic acid in managing elevated LDL-C levels.

  • #cardiology

Like

Save

Share